NCT00231465View on ClinicalTrials.gov

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

docetaxel (Taxotere®)

Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.

DRUG

ZD1839

ZD1839 will be continued until progression, or until trial closure, whichever comes first.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER